Dapagliflozin in Elderly Care

Abstract The sodium-glucose co-transporter 2 inhibitor dapagliflozin functions as a vital pharmacological treatment for type 2 diabetes mellitus (T2DM). The medication works through a distinct mechanism that does not depend on insulin production while simultaneously helping patients lose weight and manage blood pressure and reducing their risk of heart failure and chronic kidney disease thus making it an essential medication for modern healthcare practice. It demonstrates beneficial effects on cardiovascular health and renal parameters, although the precise mechanisms contributing to these advantages remain the subject of ongoing research. This review seeks to explain the current status of the drug regarding its impact on cardiovascular and renal outcomes as well as its impact on decreasing mortality rates among individuals diagnosed with T2DM. It also evaluates its efficacy, safety, and special considerations for use in the geriatric population, highlighting its unique benefits and potential risks in this age group.